Pacira ( (PCRX) ) has released its Q2 earnings. Here is a breakdown of the information Pacira presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pacira BioSciences, Inc., a leading company in the biopharmaceutical sector, specializes in developing innovative, non-opioid pain therapies. In its latest earnings report for the second quarter of 2025, Pacira reported total revenues of $181.1 million, with a net loss of $4.8 million. The company highlighted its progress in advancing its 5×30 growth strategy, focusing on expanding market adoption for its flagship product, EXPAREL.
Key financial metrics revealed net product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera°. Despite a net loss, Pacira achieved an adjusted EBITDA of $54.3 million and non-GAAP net income of $36.0 million. Strategic initiatives included a new $300 million revolving credit facility to enhance liquidity and a co-promotion agreement with Johnson & Johnson MedTech to expand ZILRETTA’s market reach.
Pacira also achieved significant milestones in its clinical and operational strategies. The Phase 2 study of PCRX-201 for osteoarthritis surpassed 50% enrollment, and the company optimized its manufacturing process for EXPAREL, improving gross margins. Additionally, Pacira secured favorable patent rulings, bolstering its intellectual property portfolio.
Looking ahead, Pacira remains committed to its growth strategy, with management expressing confidence in achieving sustainable growth and expanded market leadership for its products. The company has updated its full-year 2025 revenue guidance to a range of $730 million to $750 million, reflecting its strategic focus and operational efficiencies.